ArticleHuman molecular genetics2014
SUCLG2 identified as both a determinator of CSF Aβ1-42 levels and an attenuator of cognitive decline in Alzheimer's disease.
Open access · bronzeAbstract read
In one paragraph
Article in Human molecular genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 3 pooled it
4.0field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Genome-Wide Meta-Analysis of Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Parkinson's Disease Cohorts.Movement disorders : official journal of the Movement Disorder Society · 2023Pooled it
- Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers.Acta neuropathologica · 2022Pooled it
- Genetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive Review.Frontiers in aging neuroscience · 2021Pooled it
- Localization of SUCLA2 and SUCLG2 subunits of succinyl CoA ligase within the cerebral cortex suggests the absence of matrix substrate-level phosphorylation in glial cells of the human brain.Journal of bioenergetics and biomembranes · 2015Trial
- A new era of genome-wide association studies in the field of Alzheimer's disease and overlapping co-pathologies: lessons learned from a neuropathology-centered approach.Acta neuropathologica · 2026Review
- Reduced LACTB expression in myeloid cells is associated with elevated succinylcarnitine and reduced Alzheimer's disease risk.Research square · 2026Article
- The Gut-Brain Axis in Alzheimer's: From Microbiota Genetics to Stigmasterol's Neuroprotection Mechanism.Degenerative neurological and neuromuscular disease · 2026Article
- Individual bioenergetic capacity as a potential source of resilience to Alzheimer's disease.Nature communications · 2025Article
- Article
- Large-scale proteome and metabolome analysis of CSF implicates altered glucose and carbon metabolism and succinylcarnitine in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer's disease: findings based on urine proteomics and machine learning.Alzheimer's research & therapy · 2023Article
- The Deficits of Insulin Signal in Alzheimer's Disease and the Mechanisms of Vanadium Compounds in Curing AD.Current issues in molecular biology · 2023Review
- The Big Picture of Neurodegeneration: A Meta Study to Extract the Essential Evidence on Neurodegenerative Diseases in a Network-Based Approach.Frontiers in aging neuroscience · 2022Article
- Gene Expression Profiling of Tricarboxylic Acid Cycle and One Carbon Metabolism Related Genes for Prognostic Risk Signature of Colon Carcinoma.Frontiers in genetics · 2021Article
- Common Factors in Neurodegeneration: A Meta-Study Revealing Shared Patterns on a Multi-Omics Scale.Cells · 2020Article
- BIN1 favors the spreading of Tau via extracellular vesicles.Scientific reports · 2019Article
- A decade in psychiatric GWAS research.Molecular psychiatry · 2019Review
- Proteomics analysis identifies new markers associated with capillary cerebral amyloid angiopathy in Alzheimer's disease.Acta neuropathologica communications · 2018Article
- Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2018Review
- Genome-wide significant, replicated and functional risk variants for Alzheimer's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors at 16 institutions in 6 countries.
Alfredo RamirezDepartment of Psychiatry and Psychotherapy, Institute of Human Genetics, alfredo.ramirez@ukb.uni-bonn.de.
Wiesje M van der FlierDepartment of Neurology and Alzheimer Center, Neuroscience Campus Amsterdam, VU University Medical Center, 1081 HZ, Amsterdam, The Netherlands, Department of Epidemiology & Biostatistics, VU University Medical Center, 1007 MB, Amsterdam, The Netherlands.
Christine HeroldGerman Center for Neurodegenerative Diseases (DZNE), 53175, Bonn, Germany.
David RamonetClinical Neuroscience Unit, Department of Neurology.
Stefanie HeilmannInstitute of Human Genetics, Department of Genomics, Life & Brain Center.
Piotr LewczukDepartment of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen, and Friedrich-Alexander Universität Erlangen-Nürnberg, 91054, Erlangen, Germany.
Julius PoppDepartment of Psychiatry and Psychotherapy.
André LacourGerman Center for Neurodegenerative Diseases (DZNE), 53175, Bonn, Germany.
Dmitriy DrichelGerman Center for Neurodegenerative Diseases (DZNE), 53175, Bonn, Germany.
Eva LouwersheimerDepartment of Neurology and Alzheimer Center, Neuroscience Campus Amsterdam, VU University Medical Center, 1081 HZ, Amsterdam, The Netherlands, Department of Epidemiology & Biostatistics, VU University Medical Center, 1007 MB, Amsterdam, The Netherlands.
Markus P KummerClinical Neuroscience Unit, Department of Neurology, German Center for Neurodegenerative Diseases (DZNE), 53175, Bonn, Germany.
Carlos CruchagaDepartment of Psychiatry, Hope Center for Neurological Disorders, School of Medicine.
Per HoffmannInstitute of Human Genetics, Department of Genomics, Life & Brain Center, Division of Medical Genetics, University Hospital and Department of Biomedicine, University of Basel, CH-4058, Basel, Switzerland.
Charlotte TeunissenDepartment of Neurology and Alzheimer Center, Neuroscience Campus Amsterdam, VU University Medical Center, 1081 HZ, Amsterdam, The Netherlands, Department of Epidemiology & Biostatistics, VU University Medical Center, 1007 MB, Amsterdam, The Netherlands.
Henne HolstegeDepartment of Neurology and Alzheimer Center, Neuroscience Campus Amsterdam, VU University Medical Center, 1081 HZ, Amsterdam, The Netherlands, Department of Epidemiology & Biostatistics, VU University Medical Center, 1007 MB, Amsterdam, The Netherlands.
Johannes KornhuberDepartment of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen, and Friedrich-Alexander Universität Erlangen-Nürnberg, 91054, Erlangen, Germany.
Oliver PetersDepartment of Psychiatry, Charité, 14050, Berlin, Germany.
Adam C NajCenter for Clinical Epidemiology & Biostatistics, University of Pennsylvania, PA 19104, Philadelphia, USA.
Vincent ChourakiDepartment of Neurology, Boston University School of Medicine, MA 02118, Boston, USA, The Framingham Heart Study, MA 01702, Framingham, USA.
Céline BellenguezInserm, U744, Lille 59000, France, Université Lille 2, Lille 59000, France, Institut Pasteur de Lille, Lille 59000, France.
Amy GerrishInstitute of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics & Genomics, Cardiff University, Cardiff, UK.
International Genomics of Alzheimer's Project (IGAP)
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Reiner HeunDepartment of Psychiatry and Psychotherapy.
Lutz FrölichDepartment of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, 68159, Mannheim, Germany.
Michael HüllCentre for Geriatric Medicine and Section of Gerontopsychiatry and Neuropsychology, Medical School, University of Freiburg, 79106, Freiburg, Germany.
Lara BuscemiDepartment of Fundamental Neurosciences, UNIL, 1005 Lausanne, Switzerland and.
Stefan HermsInstitute of Human Genetics, Department of Genomics, Life & Brain Center, Division of Medical Genetics, University Hospital and Department of Biomedicine, University of Basel, CH-4058, Basel, Switzerland.
Heike KölschDepartment of Psychiatry and Psychotherapy.
Philip ScheltensDepartment of Neurology and Alzheimer Center, Neuroscience Campus Amsterdam, VU University Medical Center, 1081 HZ, Amsterdam, The Netherlands, Department of Epidemiology & Biostatistics, VU University Medical Center, 1007 MB, Amsterdam, The Netherlands.
Monique M BretelerGerman Center for Neurodegenerative Diseases (DZNE), 53175, Bonn, Germany.
Eckart RütherDepartment of Psychiatry and Psychotherapy, University of Göttingen, 37075 Göttingen, Germany.
Jens WiltfangDepartment of Psychiatry and Psychotherapy, University of Göttingen, 37075 Göttingen, Germany.
Alison GoateDepartment of Psychiatry, Department of Genetics, Washington University, St. Louis, MO 63110, USA.
Frank JessenDepartment of Psychiatry and Psychotherapy, German Center for Neurodegenerative Diseases (DZNE), 53175, Bonn, Germany.
Wolfgang MaierDepartment of Psychiatry and Psychotherapy, German Center for Neurodegenerative Diseases (DZNE), 53175, Bonn, Germany.
Michael T HenekaClinical Neuroscience Unit, Department of Neurology, German Center for Neurodegenerative Diseases (DZNE), 53175, Bonn, Germany.
Tim BeckerInstitute for Medical Biometry, Informatics, and Epidemiology, University of Bonn, 53127, Bonn, Germany, German Center for Neurodegenerative Diseases (DZNE), 53175, Bonn, Germany.
Markus M NöthenInstitute of Human Genetics, Department of Genomics, Life & Brain Center.
German Center for Neurodegenerative Diseases · DEAmsterdam Neuroscience · NLFriedrich-Alexander-Universität Erlangen-Nürnberg · DEGenomics (United Kingdom) · GBHeidelberg University · DEUniversity of Basel · CHUniversity of Bonn · DEUniversity of Freiburg · DEWashington University in St. Louis · USBoston University · USCardiff University · GBCharité - Universitätsmedizin Berlin · DEHope Center for Neurological Disorders · USInserm · FRUniversity of Lausanne · CHUniversity of Pennsylvania · US
Funding
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0MNational Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8MAlzheimer's Disease Genetics ConsortiumU01AG032984 · NIA · UNIVERSITY OF PENNSYLVANIA · PI SCHELLENBERG, GERARD DAVID · 2009 to 2024
$60.4MUC Davis Alzheimer's Disease Core CenterP30AG010129 · NIA · UNIVERSITY OF CALIFORNIA DAVIS · PI DECARLI, CHARLES · 1991 to 2020
$28.3M"MR Morphometrics and Cognitive Decline Rate in Large-Scale Aging Studies"K01AG030514 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CARMICHAEL, OWEN T. · 2008 to 2012
$495kCIHRNIA NIH HHS K01 AG030514NIA NIH HHS P30 AG010129NIA NIH HHS U01 AG024904NIA NIH HHS U01 AG032984NIA NIH HHS U24 AG021886
Abstract
Cerebrospinal fluid amyloid-beta 1-42 (Aβ1-42) and phosphorylated Tau at position 181 (pTau181) are biomarkers of Alzheimer's disease (AD). We performed an analysis and meta-analysis of genome-wide association study data on Aβ1-42 and pTau181 in AD dementia patients followed by independent replication. An association was found between Aβ1-42 level and a single-nucleotide polymorphism in SUCLG2 (rs62256378) (P = 2.5×10(-12)). An interaction between APOE genotype and rs62256378 was detected (P = 9.5 × 10(-5)), with the strongest effect being observed in APOE-ε4 noncarriers. Clinically, rs62256378 was associated with rate of cognitive decline in AD dementia patients (P = 3.1 × 10(-3)). Functional microglia experiments showed that SUCLG2 was involved in clearance of Aβ1-42.
Indexed as
Polymorphism, Single NucleotideAgedAlzheimer DiseaseAmyloid beta-PeptidesApolipoprotein E4CognitionFemaleGene Expression RegulationGenome-Wide Association StudyHumansMaleNuclear ProteinsPeptide FragmentsPhosphorylationRNA-Binding ProteinsSerine-Arginine Splicing FactorsAmyloid beta-Peptidesamyloid beta-protein (1-42)Apolipoprotein E4Nuclear ProteinsPeptide FragmentsRNA-Binding ProteinsSerine-Arginine Splicing Factorstau Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.